Macrogenics (NASDAQ: MGNX) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.65) by 9.38 percent. This is a 10.77 percent increase over losses of $(0.65) per share from the same period last year. The company reported quarterly sales of $20.775 million which beat the analyst consensus estimate of $15.050 million by 38.04 percent. This is a 57.48 percent increase over sales of $13.192 million the same period last year.